Novel Medications for Opiate Detoxification - 4

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000279

Purpose

The purpose of this study is to evaluate novel medications for opiate detoxification.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Clonidine	Phase II

Drug Information available for: Clonidine Clonidine hydrochloride

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Novel Medications for Opiate Detoxification

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:

Eligibility

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000279

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

Study ID Numbers:	NIDA-09250-4, P50-09250-4
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000279
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Mental Disorders
Clonidine
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:

Pathologic Processes
Disease

ClinicalTrials.gov processed this record on January 15, 2009